Y-mAbs Therapeutics Inc. (YMAB)
AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 6.18 |
Market Cap | 276.80M |
Revenue (ttm) | 84.86M |
Net Income (ttm) | -23.95M |
EPS (ttm) | -0.54 |
PE Ratio (ttm) | -11.44 |
Forward PE | -22.91 |
Analyst | Buy |
Ask | 6.2 |
Volume | 173,838 |
Avg. Volume (20D) | 320,576 |
Open | 6.20 |
Previous Close | 6.19 |
Day's Range | 6.02 - 6.25 |
52-Week Range | 6.01 - 20.90 |
Beta | 0.67 |
About YMAB
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developin...
Analyst Forecast
According to 10 analyst ratings, the average rating for YMAB stock is "Buy." The 12-month stock price forecast is $23, which is an increase of 272.17% from the latest price.
Next Earnings Release
Analysts project revenue of $26.94M, reflecting a 15.31% YoY growth and earnings per share of -0.12, making a 500.00% increase YoY.
Why Price Moved
We use cookies to ensure that we give you the best experience on our website. Read Privacy Policy.